Disposable processing drove investment in media biz, says SAFC

This content item was originally published on www.biopharma-reporter.com, a William Reed online publication.

By Gareth Macdonald and Claire Videau

- Last updated on GMT

Related tags: Gene

US supplier SAFC recently expanded its liquid cell culture reagents in response to growing biomanufacturing industry demand.

SAFC Pharma vice president David Feldker spoke with in-pharmatechnologist about the firm’s reasons for investing $12m (€9.7m) at facilities in St Louis, Missouri site and Irvine, Scotland.

Foremost among these, according to Feldker, is the push towards disposable processing technology in the biomanufacturing industry is driving demand for liquid media and the preparation of specialist reagents.

Feldker went on to explain that the investment also fits with the recently announced expansion of its dry powder media manufacturing facility in Lenexa, Kansas and wider expansion of SAFC’s range of cell culture technologies.

And for the medium term Feldker expects the biodrug sector to continue to drive demand. He suggested that the growth of the gene therapy market and personalised medicine sector, coupled with the need to reduce production costs and boost efficiency would remain.

Related news

Show more

Related products

show more

A Culture of Innovation as a Differentiation

A Culture of Innovation as a Differentiation

Softigel by Procaps | 06-Dec-2021 | Product Presentation

We create safe, effective and differentiated pharmaceutical solutions and this has been our goal since day 1. The main driver of our growth is innovation...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Follow us